Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior

被引:50
|
作者
Rajagopalan, Ravi [1 ]
Misialck, Shawn [1 ]
Stevens, Sarah K. [1 ]
Myszka, David G. [2 ]
Brandhuber, Barbara J. [3 ]
Ballard, Joshua A. [3 ]
Andrews, Steven W. [3 ]
Seiwert, Scott D. [1 ]
Kossen, Karl [1 ]
机构
[1] InterMune Inc, Brisbane, CA 94005 USA
[2] Biosensor Tools, Salt Lake City, UT 84132 USA
[3] Array Biopharma, Boulder, CO 80301 USA
关键词
NS4A COFACTOR PEPTIDE; HUMAN-IMMUNODEFICIENCY-VIRUS; TIME-DEPENDENT INHIBITION; SERINE-PROTEASE; CRYSTAL-STRUCTURE; ANTIVIRAL EFFICACY; COMPLEX-FORMATION; PLUS RIBAVIRIN; IN-VITRO; INFECTION;
D O I
10.1021/bi900038p
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The protease activity of hepatitis C virus nonstructural protein 3 (NS3) is essential for viral replication. ITMN-191, a macrocyclic inhibitor of the NS3 protease active site, promotes rapid, multilog viral load reductions in chronic HCV patients. Here, ITMN-191 is shown to be a potent inhibitor of NS3 with a two-step binding mechanism. Progress curves are consistent with the formation or an initial collision complex (EI) that isomerizes to a highly stable complex (EI*) from which ITMN-191 dissociates very slowly. K-i, the dissociation constant of El, is 100 nM, and the rate constant for conversion of EI to EI* is 6.2 x 10(-2) s(-1). Binding experiments using protein fluorescence confirm this isomerization rate. From progress curve analysis, the rate constant for dissociation of ITMN-191 from the EI* complex is 3.8 x 10(-5) s(-1) with a calculated complex half-life of similar to 5 h and a true biochemical potency (K-i*) of similar to 62 pM. Surface plasmon resonance studies and assessment of enzyme reactivation following dilution of the EI* complex confirm slow dissociation and suggest that the half-life may be considerably longer. Abrogation of the tight binding and slow dissociative properties of ITMN-191 is observed with proteases that carry the R155K or D168A substitution, each of which is likely in drug resistant mutants. Slow dissociation is not observed with closely related macrocyclic inhibitors of NS3, suggesting that members of this class may display distinct binding kinetics.
引用
收藏
页码:2559 / 2568
页数:10
相关论文
共 50 条
  • [1] Characterization of HCV Ns3/4a protease inhibition by Itmn-191 reveals picomolar potency and slow dissociation: Implications for the use of Itmn-191 in chronic HCV treatment
    Rajagopalan, P. I. Ravi
    Misialek, Shawn
    Blatt, Lawrence M.
    Seiwert, Scott D.
    Kossen, Karl
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A782 - A782
  • [2] Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)
    Seiwert, Scott D.
    Andrews, Steven W.
    Jiang, Yutong
    Serebryany, Vladimir
    Tan, Hua
    Kossen, Karl
    Rajagopalan, P. T. Ravi
    Misialek, Shawn
    Stevens, Sarah K.
    Stoycheva, Antitsa
    Hong, Jin
    Lim, Sharlene R.
    Qin, Xiaoli
    Rieger, Robert
    Condroski, Kevin R.
    Zhang, Hailong
    Do, Mary Geck
    Lemieux, Christine
    Hingorani, Gary P.
    Hartley, Dylan P.
    Josey, John A.
    Pan, Lin
    Beigelman, Leonid
    Blatt, Lawrence M.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (12) : 4432 - 4441
  • [3] Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease
    Jiang, Yutong
    Andrews, Steven W.
    Condroski, Kevin R.
    Buckman, Brad
    Serebryany, Vlad
    Wenglowsky, Steve
    Kennedy, April L.
    Madduru, Machender R.
    Wang, Bin
    Lyon, Michael
    Doherty, George A.
    Woodard, Benjamin T.
    Lemieux, Christine
    Do, Mary Geck
    Zhang, Hailong
    Ballard, Joshua
    Vigers, Guy
    Brandhuber, Barbra J.
    Stengel, Peter
    Josey, John A.
    Beigelman, Leonid
    Blatt, Lawrence
    Seiwert, Scott D.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (05) : 1753 - 1769
  • [4] α-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease
    Narjes, F
    Brunetti, M
    Colarusso, S
    Gerlach, B
    Koch, U
    Biasiol, G
    Fattori, D
    De Francesco, R
    Matassa, VG
    Steinkühler, C
    [J]. BIOCHEMISTRY, 2000, 39 (07) : 1849 - 1861
  • [5] RNA binding by the NS3 protease of the hepatitis C virus
    Vaughan, Robert
    Li, Yi
    Fan, Baochang
    Ranjith-Kumar, C. T.
    Kao, C. Cheng
    [J]. VIRUS RESEARCH, 2012, 169 (01) : 80 - 90
  • [6] Thermodynamics of zinc binding to hepatitis C virus NS3 protease: A folding by binding event
    Abian, Olga
    Luis Neira, Jose
    Velazquez-Campoy, Adrian
    [J]. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2009, 77 (03) : 624 - 636
  • [7] In vitro synergistic antiviral activity of ITMN-191, an orally active inhibitor of the hepatitis C virus (HCV) NS3/4A protease, in combination with PEG-Interferon alfa-2A
    Tan, Hua
    Seiwert, Scott D.
    Blatt, Lawrence M.
    [J]. HEPATOLOGY, 2006, 44 (04) : 534A - 534A
  • [8] Product inhibition of the hepatitis C virus NS3 protease
    Steinkühler, C
    Biasiol, G
    Brunetti, M
    Urbani, A
    Koch, U
    Cortese, R
    Pessi, A
    De Francesco, R
    [J]. BIOCHEMISTRY, 1998, 37 (25) : 8899 - 8905
  • [9] Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor
    Heintges, T
    Encke, J
    Putlitz, JZ
    Wands, JR
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2001, 65 (04) : 671 - 680
  • [10] The RNA aptamer-binding site of hepatitis C virus NS3 protease
    Hwang, J
    Fauzi, H
    Fukuda, K
    Sekiya, S
    Kakiuchi, N
    Shimotohno, K
    Taira, K
    Kusakabe, I
    Nishikawa, S
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 279 (02) : 557 - 562